Hunter Syndrome
📧 Sign up to get email alerts when something new happens for Hunter Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) [Phase 3]
Phase 3 clinical trial update for RGX-121-3102 gene therapy in MPS II (Hunter syndrome) is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age [Phase 4]
Phase 4 long-term study assessing height and weight outcomes in children with Mucopolysaccharidosis type II (Hunter syndrome) who began idur…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) [Phase 3]
An extension Phase 3 trial update to assess the long-term safety and efficacy of Hunterase (Idursulfase Beta) in Mucopolysaccharidosis type …
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis [Phase 2]
Phase 2 trial update describing allogeneic hematopoietic cell transplantation for metabolic disorders and severe osteopetrosis, with the stu…
-
CLINICAL_TRIALS withdrawal · 2025-12-09Clinical Trial Update: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) [Phase 4]
A Phase 4 trial of Elaprase (idursulfase) in treatment-naïve patients with Hunter syndrome has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment [Phase 2, Phase 3]
This clinical trial update describes an extension study of Idursulfase-IT in combination with Elaprase for children and adults with Hunter s…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment [Phase 1, Phase 2]
An extension Phase 1/2 study evaluating the long-term safety and clinical outcomes of combining Idursulfase-IT with Elaprase in pediatric pa…
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094 [Phase 2, Phase 3]
ClinicalTrials.gov update reporting long-term safety and clinical outcomes of idursulfase IT and Elaprase in pediatric participants who comp…
-
CLINICAL_TRIALS trial_result · 2024-04-16Clinical Trial Update: A Study of GC1111 in Hunter Syndrom Patients [Phase 3]
Phase 3 trial of GC1111 in Hunter syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2018-12-13Clinical Trial Update: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment [Phase 2, Phase 3]
A study evaluating intrathecal idursulfase-IT with Elaprase in pediatric Hunter syndrome patients with early cognitive impairment has comple…
-
FDA approval · 2018-11-16FDA Approved: ELAPRASE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Elaprase (idursulfase) by Takeda Pharmaceuticals America, Inc., related to changes or additi…
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Clinical trial update reporting screening for pediatric Hunter syndrome patients on Elaprase to identify CNS involvement; study status Compl…
-
CLINICAL_TRIALS trial_result · 2014-12-05Clinical Trial Update: Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Completed clinical trial studying cerebrospinal fluid collection in patients with Hunter syndrome; results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-07-30Clinical Trial Update: An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
An observational study evaluating anti-idursulfase serum antibody response in Hunter Syndrome patients has been completed with results poste…
-
CLINICAL_TRIALS research · 2014-06-20Clinical Trial Update: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
This update provides information on the ongoing long-term safety study of Idursulfase-beta in patients with Hunter syndrome (Mucopolysacchar…
-
CLINICAL_TRIALS trial_result · 2014-05-16Clinical Trial Update: A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® [Phase 1, Phase 2]
A safety and dose-ranging study assessing intrathecal idursulfase via an intrathecal delivery device in pediatric Hunter syndrome patients w…
-
CLINICAL_TRIALS trial_result · 2014-03-17Clinical Trial Update: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase [Phase 2, Phase 3]
Extension study update for long-term safety and outcomes in MPS II patients treated with idursulfase (Hunter syndrome).
-
CLINICAL_TRIALS trial_result · 2013-11-07Clinical Trial Update: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy [Phase 4]
Phase 4 trial update on safety and clinical outcomes in young children with Hunter syndrome treated with idursulfase.
-
FDA label_change · 2013-06-24FDA Approved: ELAPRASE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ELAPRASE (idursulfase) from Takeda Pharmaceuticals America, Inc.
-
FDA approval ·FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
FDA approved Avlayah (tividenofusp alfa-eknm) to treat neurologic manifestations in individuals with Hunter syndrome (MPS II).